Biohaven posts q3 loss of $2.04/shr

Biohaven pharmaceuticals reports third quarter 2019 financial results and recent business developments.q3 loss per share $2.04.q3 earnings per share estimate $-1.57 -- refinitiv ibes data.expected pdufa date of q1 of 2020 for zydis orally dissolving tablet formulation.cash as of september 30, 2019, was $416.6 million, compared to $465.7 million as of june 30, 2019.

BHVN Ratings Summary

BHVN Quant Ranking